Ceftaroline fosamilCAS# 400827-46-5 |
- Pefloxacin Mesylate Dihydrate
Catalog No.:BCC5089
CAS No.:149676-40-4
- Besifloxacin HCl
Catalog No.:BCC4764
CAS No.:405165-61-9
- Norfloxacin hydrochloride
Catalog No.:BCC4230
CAS No.:68077-27-0
- Pefloxacin
Catalog No.:BCC4231
CAS No.:70458-92-3
- Pefloxacin Mesylate
Catalog No.:BCC4821
CAS No.:70458-95-6
- Norfloxacin
Catalog No.:BCC4688
CAS No.:70458-96-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 400827-46-5 | SDF | Download SDF |
| PubChem ID | 56841980 | Appearance | Powder |
| Formula | C24H25N8O10PS4 | M.Wt | 744.74 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 30 mg/mL (40.28 mM; Need ultrasonic and warming) | ||
| Chemical Name | (6R,7R)-7-[[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;acetate | ||
| SMILES | CCON=C(C1=NSC(=N1)NP(=O)(O)O)C(=O)NC2C3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)O.CC(=O)[O-] | ||
| Standard InChIKey | UGHHNQFYEVOFIV-VRDMTWHKSA-N | ||
| Standard InChI | InChI=1S/C22H21N8O8PS4.C2H4O2/c1-3-38-26-13(16-25-21(43-28-16)27-39(35,36)37)17(31)24-14-18(32)30-15(20(33)34)12(9-40-19(14)30)42-22-23-11(8-41-22)10-4-6-29(2)7-5-10;1-2(3)4/h4-8,14,19H,3,9H2,1-2H3,(H4-,24,25,27,28,31,33,34,35,36,37);1H3,(H,3,4)/b26-13-;/t14-,19-;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Ceftaroline fosamil Dilution Calculator
Ceftaroline fosamil Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.3428 mL | 6.7138 mL | 13.4275 mL | 26.855 mL | 33.5688 mL |
| 5 mM | 0.2686 mL | 1.3428 mL | 2.6855 mL | 5.371 mL | 6.7138 mL |
| 10 mM | 0.1343 mL | 0.6714 mL | 1.3428 mL | 2.6855 mL | 3.3569 mL |
| 50 mM | 0.0269 mL | 0.1343 mL | 0.2686 mL | 0.5371 mL | 0.6714 mL |
| 100 mM | 0.0134 mL | 0.0671 mL | 0.1343 mL | 0.2686 mL | 0.3357 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 20-Hydroxyganoderic acid G
Catalog No.:BCN8231
CAS No.:400604-12-8
- N6-Benzoyladenine
Catalog No.:BCC9075
CAS No.:4005-49-6
- SU 3327
Catalog No.:BCC7725
CAS No.:40045-50-9
- Syringetin-3-O-glucoside
Catalog No.:BCN2610
CAS No.:40039-49-4
- 24, 25-Dihydroxy VD3
Catalog No.:BCC1303
CAS No.:40013-87-4
- H-Thr-OMe.HCl
Catalog No.:BCC3104
CAS No.:39994-75-7
- Laricitrin 3-O-glucoside
Catalog No.:BCN8149
CAS No.:39986-90-8
- p-Hydroxy-5,6-dehydrokawain
Catalog No.:BCN3597
CAS No.:39986-86-2
- Delta-9-Tetrahydrocannabivarinic acid
Catalog No.:BCN7967
CAS No.:39986-26-0
- HOAt
Catalog No.:BCC2815
CAS No.:39968-33-7
- Victoxinine
Catalog No.:BCN6745
CAS No.:39965-06-5
- LY 78335
Catalog No.:BCC6109
CAS No.:39959-66-5
- H-Arg-pNA.2HCl
Catalog No.:BCC2858
CAS No.:40127-11-5
- Erucifoline
Catalog No.:BCN2081
CAS No.:40158-95-0
- Boc-N-Me-Phe.DCHA
Catalog No.:BCC3348
CAS No.:40163-88-0
- SKA 31
Catalog No.:BCC7743
CAS No.:40172-65-4
- Andarine
Catalog No.:BCC1168
CAS No.:401900-40-1
- Fmoc-β-homo-Arg(Pbf)-OH
Catalog No.:BCC2649
CAS No.:401915-53-5
- Fmoc-β-Homo-Gln(Trt)-OH
Catalog No.:BCC2647
CAS No.:401915-55-7
- H-Orn-OMe.2HCl
Catalog No.:BCC3001
CAS No.:40216-82-8
- H-Hyp-OMe.HCl
Catalog No.:BCC3248
CAS No.:40216-83-9
- 5-O-Feruloylquinic acid
Catalog No.:BCN3788
CAS No.:40242-06-6
- Glycitin
Catalog No.:BCN5895
CAS No.:40246-10-4
- ONO-AE3-208
Catalog No.:BCC1822
CAS No.:402473-54-5
Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.[Pubmed:27895012]
Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: AAC.02015-16.
Novel therapies for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) are needed in the setting of reduced antibiotic susceptibilities and therapeutic failure. Ceftaroline is a cephalosporin antibiotic with MRSA activity. Although not FDA approved for MRSA BSI, ceftaroline has generated much interest as a potential treatment option. However, detailed descriptions of its use in this setting remain limited. To address this, we conducted a retrospective, multicenter, observational study of adult patients with MRSA BSI treated with at least 72 h of ceftaroline from 2011 to 2015. Safety outcomes were examined in the overall cohort, while efficacy outcomes were examined among patients who had not cleared their BSI prior to ceftaroline initiation. Data were also stratified by ceftaroline monotherapy or combination therapy. Predictors of clinical failure on ceftaroline treatment were also sought. Overall, 211 patients were included in the safety population; Clostridium difficile infection, rash, and neutropenia occurred in 6 patients (2.8%), 7 patients (3.3%), and 3 patients (1.4%), respectively. Clinical success was observed in 86 (68.3%) of the 126 patients included in the efficacy population. The monotherapy and combination therapy subgroups had similar proportions of patients experiencing success (69.7 and 64.9%, respectively). The median BSI durations post-ceftaroline treatment were 2 days (interquartile range, 1 to 4 days) for monotherapy and 3 days (interquartile range, 1.5 to 5 days) for combination therapy. Higher acute physiology and chronic health evaluation II scores and comorbid malignancy independently predicted treatment failure. Ceftaroline appears effective for MRSA BSI as both monotherapy and combination therapy. However, comparative studies are needed to further delineate the role of ceftaroline in MRSA BSI treatment.
Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application.[Pubmed:28039666]
Infect Dis Ther. 2017 Mar;6(1):57-67.
Ceftaroline is a novel cephalosporin recently approved in children for treatment of acute bacterial skin and soft tissue infections and community-acquired bacterial pneumonia (CABP) caused by methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae and other susceptible bacteria. With a favorable tolerability profile and efficacy proven in pediatric patients and excellent in vitro activity against resistant Gram-positive and Gram-negative bacteria, ceftaroline may serve as a therapeutic option for polymicrobial infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and resistant Gram-positive infections that fail first-line antimicrobial agents. However, limited data are available on tolerability in neonates and infants younger than 2 months of age, and on pharmacokinetic characteristics in children with chronic medical conditions and those with invasive, complicated infections. In this review, the microbiological profile of ceftaroline, its mechanism of action, and pharmacokinetic profile will be presented. Additionally, clinical evidence for use in pediatric patients and proposed place in therapy is discussed.
Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review.[Pubmed:28058593]
Int J Clin Pharm. 2017 Feb;39(1):26-32.
Background Ceftaroline is a parentally administered cephalosporin that has an in vitro expanded spectrum of activity compared with other cephalosporins yet data is conflicting regarding its place in therapy. Aim of the Review To compare the efficacy and safety of ceftaroline against standard antibiotic regimens for community-acquired pneumonia (CAP) and complicated skin and skin structure infections (cSSSIs). Method The databases of MEDLINE, EBSCO, and Embase were searched up to June 2016. Manual review of references was completed and experts in the field were contacted for unpublished data. Randomized controlled trials of ceftaroline in CAP or cSSSI populations were included. Outcomes included clinical cure, mortality, adverse events, serious adverse events, and discontinuation due to adverse events. Meta-analysis was used to pool results for these outcomes. We performed subgroup analyses for gram positive infections in CAP and infections caused by methicillin-resistant Staphylococcus aureus in cSSSIs. Risk of bias was assessed for all studies. Results Six trials (three for each indication) were included, each of which had an unclear or high risk of bias in at least one domain. For CAP, ceftaroline was significantly more efficacious in achieving clinical cure than ceftriaxone [risk ratio (RR) 1.11, 95% confidence interval (CI) 1.04-1.19; I(2) = 47%]. For cSSSIs, there was no significant difference in clinical cure between ceftaroline and vancomycin plus aztreonam (RR 1.01, 95% CI 0.97-1.05; I(2) = 0%). No differences were found for overall mortality, serious adverse events, discontinuation due to adverse events, and overall adverse events. Conclusion Ceftaroline is a viable therapeutic alternative for patients with CAP and cSSSIs, yet identified risks of bias and poor external validity preclude it from being recommended as a first-line agent.
Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.[Pubmed:28131729]
Int J Infect Dis. 2017 Apr;57:27-31.
OBJECTIVES: Vancomycin is the treatment of choice for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia; however, its use has been subject to scrutiny due to failure in severe infections. Ceftaroline fosamil (CPT-F) is approved for MRSA acute bacterial skin and skin structure infections, but not for bloodstream infections. The clinical outcomes of treatment with CPT-F in patients with MRSA bacteremia were evaluated. METHODS: Patients diagnosed with MRSA bacteremia at Henry Ford Hospital in Detroit, Michigan, USA, involving isolates with a vancomycin minimum inhibitory concentration >/=1.0mg/l and susceptible in vitro to CPT-F, were systematically reviewed retrospectively. Ceftaroline fosamil-treated patients were matched with at least two vancomycin- and/or one daptomycin-treated control patient based on age-patients age 65 years or greater or less than 65 years of age. Outcomes evaluated included the duration of hospitalization, duration of therapy, adverse events, relapse, hospital readmission, and death. RESULTS: Thirty consecutive cases of MRSA bacteremia treated with CPT-F during the period May 2011 to June 2013 were identified; these patients were matched to 56 MRSA bacteremia patients treated with vancomycin and 46 MRSA bacteremia patients treated with daptomycin. The primary source of MRSA bacteremia in the cohort treated with CPT-F was endocarditis (n=7, 23%), skin/wound (n=9, 30%), and bone/joint (n=8, 27%). The MRSA bacteremia in those treated with CPT-F was community-acquired in 43% of cases, healthcare-associated in 43%, and hospital-acquired in 13%. The mean length of hospital stay for these patients was 22 days. The overall 30-day mortality rate was 13% (n=4) in CPT-F patients versus 24% (n=11) in daptomycin patients and 11% (n=6) in vancomycin patients (p=0.188). CONCLUSIONS: CPT-F demonstrated comparable clinical outcomes in MRSA bacteremia patients compared with the other agents, especially as salvage therapy.
